To overcome this, a very recent study [57] designed new dual targets that act on HDAC and on proteasome, based on other studies that suggest that overexpression HDAC might related to resistance of multiple myeloma to bortezomib. This evidence concerns the gene HDAC9 and plasma cell myeloma.